[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"calcific-aortic-valve-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:calcific-aortic-valve-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100638082","derivation-and-validation-of-the-aortic-valve-echocardiographic-calcium-score-to-confirm-severe-aortic-stenosis-the-echo-avcs-study-100638082",false,"NCT07620925","Derivation and Validation of the Aortic Valve Echocardiographic Calcium Score to Confirm Severe Aortic Stenosis: the Echo-AVCS Study","Echo-AVCS","Inclusion Criteria:\n\n* Age \\> 18 years old\n* Clinical indication for standard transthoracic echocardiography.\n* Clinical indication for cardiac CT with available calcium score.\n* 3-month time interval between transthoracic echocardiography and cardiac CT.\n* Able to give informed consent.\n\nExclusion Criteria:\n\n* Patients with inadequate transthoracic echocardiographic images.\n* Poor quality cardiac CT, inadequate for standard calcium score assessment.\n* Patients with known prior stents and\u002For coronary artery bypass grafts.\n* Patients with known previous percutaneous or surgical aortic valve replacement.\n* Patients with active or a history of endocarditis.\n* Patients with congenital heart defects (other than isolated bicuspid aortic valve).","ALL","18 Years",{"count":19,"type":20},250,"ESTIMATED","1 Year","OBSERVATIONAL","The Echo-AVCS Study is an investigator-initiated, prospective, multicenter observational study designed to derive and validate an artificial intelligence (AI)-based echocardiographic aortic valve calcium score (Echo-AVCS) for confirming severe aortic stenosis (AS). Transthoracic echocardiography (TTE) is the standard imaging modality for assessing AS severity; however, discrepancies between valve area and transvalvular gradient measurements may complicate diagnosis, particularly in low-flow or discordant AS presentations. Cardiac computed tomography (CT)-derived aortic valve calcium scoring is currently used to resolve diagnostic uncertainty, but it involves additional cost and radiation exposure. This study will enroll consecutive adult patients undergoing clinically indicated TTE and cardiac CT with calcium scoring performed within 3 months. Standardized echocardiographic images will be centrally analyzed using dedicated AI-based image segmentation and machine learning methods to quantify aortic valve calcification directly from TTE images. CT-derived aortic valve calcium score will serve as the reference standard. The primary objective is to derive and validate the Echo-AVCS score for identifying severe AS. Secondary objectives include determination of sex-specific diagnostic thresholds, correlation with CT calcium volume, association with symptoms and NYHA class, and evaluation of prognostic associations with aortic valve replacement, heart failure hospitalization, cardiovascular events, and mortality at 1-year follow-up.",[25,26,27,28],"Aortic Stenosis","Chronic Coronary Syndrome","Calcific Aortic Valve Disease","Calcific Aortic Stenosis",[30,31,32,33,34],"Aortic stenosis","Low-flow","Aortic valve calcium score","Echocardiography","Cardiac-CT","RECRUITING","2026-06-03",{"date":38,"type":39},"2026-06-04","ACTUAL",{"date":41,"type":39},"2026-03-01",{"date":43,"type":20},"2027-12-31",{"name":45,"class":46},"Azienda Ospedaliera \"Sant'Andrea\"","OTHER",5,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100599949","phase-2-exploration-of-manidipine-to-reverse-aortic-valve-calcification-100599949","NCT07091136","Exploration of Manidipine to Reverse Aortic Valve Calcification","Exploration of Manidipine to Reverse Aortic Valve Calcification by Activating Valvular Osteoclasts in Patients With Severe Calcific Aortic Valvular Disease","Inclusion Criteria:\n\n* Male or female adult ≥ 60 years of age at the time of rescruiting.\n* Subject has calcific aortic valve disease with mild to moderate aortic valve stenosis as defined by Doppler echocardiography results: Aortic Valve mean pressure gradient between 10-30 mmHg and Aortic Valve Area ≥ 1.2 and ≤ 2.0 cm2 on TTE within 2 weeks prior to randomization and Cardiac Compute Tomography (CT) test results: aortic valve calcium score (Agatston score) ≥ 200 AU at baseline cardiac CT within 1 month prior to randomization\n* Subject provides written informed consent prior to initiation of any study procedures.\n* Subject understands and agrees to comply with planned study procedures.\n\nExclusion Criteria:\n\n* Subject has concomitant moderate or severe mitral or tricuspid valve disease.\n* Subject has left ventricular ejection fraction \\\u003C 50%.\n* Subject previous history of aortic valve surgery, pancreatitis, malignant tumor, drug or alcohol abuse.\n* Subjects whose alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\> 2.5 times the upper limit of normal range.\n* Subjects who cannot undergo Cardiac CT.\n* Pregnant or lactating women.\n* Consideration by the investigator, for safety reasons, that the subject is an unsuitable candidate to receive study treatment.","60 Years","85 Years",{"count":58,"type":20},100,"INTERVENTIONAL",[61],"PHASE2","This is a prospective, randomized, comparative, clinical trial conducted by Wuhan Union Hospital that aims to evaluate the efficacy and safety of manidipine compared to placebo in patients with calcific aortic valve disease with mild aortic valve stenosis.",[27],[65,66],"manidipine","Calcific Aortic Valve disease","NOT_YET_RECRUITING","2025-07-21",{"date":70,"type":39},"2025-07-29",{"date":72,"type":20},"2025-08-01",{"date":74,"type":20},"2026-10-31",{"name":76,"class":46},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology"]